Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a randomised, double-blind, placebo-controlled Phase 1/2 clinical trial to evaluate the safety, tolerability and immunogenicity of recombinant respiratory syncytial virus in participants aged 18 years and older.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-23; most recent amendment 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2025-02-11
Trial Details
NCT Number NCT06754605
Lead Sponsor Sinocelltech Ltd.
Conditions Respiratory Syncytial Virus
Enrollment 480 participants
Start Date 2025-02-06
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-13